mushroom blend on oxygen kinetics

Conditions: Oxygen Utilization; Oxygen Kinetics

Summary: purpose: to determine the acute effects of a mushroom blend vs. placebo on oxygen kinetics, aerobic power and time to fatigue in healthy adults.

participants: twenty-eight, healthy, active, recreationally-trained adults ages 18-35. procedures (methods): all subjects will report to the applied physiology laboratory in fetzer rm 025 for phase i of the study for a total of 7 visits. a randomly selected subset of 8 participants will continue to phase ii, and return to the lab for an additional 3 visits to evaluate feasibility. visit 1 will consist of a physical, enrollment and consenting. visits, 2, 3, and 4 will be separated by a minimum of 24 hours. during visit 2, participants will perform a maximal oxygen consumption (vo2max) test on a cycle ergometer. during visit 3 participants will be asked to complete a 6-minute oxygen kinetics test on a cycle ergometer; lactate threshold and oxygen saturation will be measured at baseline, minutes 2, 3 and 6 during the 6 min ride. during visit 4, participants will perform a 3-minute critical power (cp) test and will provide a saliva sample, to be measured for cortisol levels, immediately prior to and after the cp test. following visit 4, participants will be randomly assigned, in a double-blind fashion, to either a placebo or mushroom blend treatment group. participants in the placebo and treatment groups will be asked to consume 2 servings, 3 times daily for 7 days. following supplementation, participants will return to the laboratory for visits 5-7, each of which will be separated by a minimum of 24 hours. the same protocol performed during visits 2-4 will be repeated in the same order for visits 5-7; the vo 2max test, the 6 min oxygen kinetics test, and the cp test with a pre and post saliva sample. the randomly selected subset of 8 participants will continue into phase ii (n=4 for treatment; n=4 for placebo). during phase ii, the 8 participants in the placebo and treatment groups will be asked to consume 2 servings, 3 times daily for 14 additional days to determine feasibility of a longer supplementation phase. following supplementation, the same protocol performed during visits 2-4 will be repeated in the same order for visits 8-10, each of which will be separated by a minimum of 24 hours.

Eligibility criteria:
inclusion criteria: * participant has been involved in exercise program for a minimum of one year prior to recruitment (≥ 3 d/wk) * participant is able to exercise (i.e. no existing musculoskeletal injury) * participant is willing and able to comply with the protocol * participant is apparently healthy and free from disease, as determined by a health history questionnaire and physical * participant agrees to abstain from smoking, caffeine, tobacco, and alcohol before testing days * participant agrees to abstain from exercise 24 hours prior to each testing visit * participant is not allergic to mushrooms exclusion criteria: * participant has a bmi ≤ 28 kg/m² (pre-screening inclusion) * having a history of medical or surgical events that may significantly affect the study outcome, including cardiovascular disease, metabolic, renal, hepatic, or musculoskeletal disorders * participant is using, or has used one of the following dietary supplements within 12 weeks prior to enrollment: beta-alanine, creatine, carnosine or taurine * participant has lost or gained greater than ten pounds within the previous 3 month * participant is currently enrolled in another clinical trial. * participant has a known allergy or sensitivity to any ingredient in the test product or placebo (determined from health history questionnaire)

Keywords: cordyceps, aerobic capacity, exercise performance, fatigue